$BDPT
BIOADAPTIVES, INC. Stock $bdpt

$bdpt Overview Financials Valuation SEC Filings Company Website

2022 Q2 Form 10-Q Financial Statement

#000164033422000978 Filed on May 12, 2022

Income Statement

Concept	2022 Q2	2022 Q1	2021 Q1
Revenue	$4.322K	$5.533K	$4.520K
YoY Change	-28.74%	22.41%	-3.0%
Cost Of Revenue	$2.169K	$3.590K	$2.022K
YoY Change	-20.05%	77.55%	48.68%
Gross Profit	$2.153K	$1.943K	$2.496K
YoY Change	-35.77%	-22.16%	-24.36%
Gross Profit Margin	49.81%	35.12%	55.22%
Selling, General & Admin	$121.6K	$143.0K	$194.5K
YoY Change	146.56%	-26.47%	37.08%
% of Gross Profit	5649.33%	7361.3%	7792.87%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$23.82K	$33.17K	$21.88K
YoY Change	-7.03%	51.6%
% of Gross Profit	1106.36%	1707.15%	876.6%
Operating Expenses	$145.5K	$176.2K	$216.4K
YoY Change	94.05%	-18.57%	52.49%
Operating Profit	-$143.3K	-$174.3K	-$213.9K
YoY Change	100.13%	-18.53%	54.32%
Interest Expense	$75.37K	$30.10K	$61.42K
YoY Change	376.01%	-50.99%	-161.84%
% of Operating Profit
Other Income/Expense, Net	-$80.54K	-$192.9K	-$278.0K
YoY Change	-66.11%	-30.62%
Pretax Income	-$223.8K	-$367.1K	-$491.9K
YoY Change	-27.62%	-25.37%	106.75%
Income Tax
% Of Pretax Income
Net Earnings	-$223.8K	-$367.1K	-$491.9K
YoY Change	-27.62%	-25.37%	106.75%
Net Earnings / Revenue	-5179.01%	-6635.3%	-10882.81%
Basic Earnings Per Share
Diluted Earnings Per Share	-$3.314K	-$6.836K	-$17.48K
COMMON SHARES
Basic Shares Outstanding	67.37M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2022 Q2	2022 Q1	2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$49.58K	$55.96K	$27.50K
YoY Change	-29.44%	103.49%	128.03%
Cash & Equivalents	$49.52K	$55.79K	$24.23K
Short-Term Investments	$60.00	$170.00	$3.280K
Other Short-Term Assets	$1.000K	$1.000K	$1.500K
YoY Change		-33.33%
Inventory	$10.65K	$3.570K	$12.29K
Prepaid Expenses	$1.000K
Receivables
Other Receivables
Total Short-Term Assets	$61.23K	$60.53K	$41.29K
YoY Change	-24.38%	46.6%	54.59%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$8.150K	$26.54K	$80.63K
YoY Change	-85.18%	-67.08%
TOTAL ASSETS
Total Short-Term Assets	$61.23K	$60.53K	$41.29K
Total Long-Term Assets	$8.150K	$26.54K	$80.63K
Total Assets	$69.38K	$87.07K	$121.9K
YoY Change	-48.98%	-28.58%	356.46%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.503K	$324.9K	$57.26K
YoY Change	-97.01%	467.45%	18.06%
Accrued Expenses	$3.146K	$73.09K
YoY Change	-29.98%
Deferred Revenue
YoY Change
Short-Term Debt	$450.3K	$427.4K	$445.3K
YoY Change	-13.91%	-4.02%	-1.75%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.564M	$1.485M	$1.165M
YoY Change	5.14%	27.53%	15.18%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.564M	$1.485M	$1.165M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$1.564M	$1.485M	$1.165M
YoY Change	5.14%	27.53%	15.18%
SHAREHOLDERS EQUITY
Retained Earnings	-$7.247M	-$7.247M
YoY Change
Common Stock	$7.746K
YoY Change	134.51%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$1.495M	-$1.398M	-$1.043M
YoY Change
Total Liabilities & Shareholders Equity	$69.38K	$87.07K	$121.9K
YoY Change	-48.98%	-28.58%	356.46%

Cashflow Statement

Concept	2022 Q2	2022 Q1	2021 Q1
OPERATING ACTIVITIES
Net Income	-$223.8K	-$367.1K	-$491.9K
YoY Change	-27.62%	-25.37%	106.75%
Depreciation, Depletion And Amortization	$23.82K	$33.17K	$21.88K
YoY Change	-7.03%	51.6%
Cash From Operating Activities	-$71.99K	-$61.16K	-$60.36K
YoY Change	142.31%	1.32%	42.66%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	65.72K	$34.01K	$80.00K
YoY Change	-12.37%	-57.49%	92.08%
NET CHANGE
Cash From Operating Activities	-71.99K	-$61.16K	-$60.36K
Cash From Investing Activities
Cash From Financing Activities	65.72K	$34.01K	$80.00K
Net Change In Cash	-6.270K	-$27.15K	$19.64K
YoY Change	-113.84%	-238.23%	-3075.61%
FREE CASH FLOW
Cash From Operating Activities	-$71.99K	-$61.16K	-$60.36K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	us-gaap	Revenues Revenues	5533	USD
CY2022Q1	us-gaap	Cost Of Revenue CostOfRevenue	3590	USD
CY2021Q1	us-gaap	Cost Of Revenue CostOfRevenue	2022	USD
CY2022Q1	us-gaap	Gross Profit GrossProfit	1943	USD
CY2022Q1	us-gaap	Derivative Liabilities DerivativeLiabilities	732867	USD
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	67367483	shares
CY2021Q1	us-gaap	Gross Profit GrossProfit	2496	USD
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	105200	USD
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8630	USD
CY2022Q1	us-gaap	Professional Fees ProfessionalFees	37832	USD
CY2021Q1	us-gaap	Professional Fees ProfessionalFees	21983	USD
CY2022Q1	bdpt	Stock Based Compensation StockBasedCompensation	0	USD
CY2021Q1	bdpt	Stock Based Compensation StockBasedCompensation	163900	USD
CY2022Q1	bdpt	Amortization Of License AmortizationOfLicense	33167	USD
CY2021Q1	bdpt	Amortization Of License AmortizationOfLicense	21875	USD
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	176199	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	216388	USD
CY2022Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-21	USD
CY2021Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	2834	USD
CY2022Q1	us-gaap	Interest Expense InterestExpense	30099	USD
CY2021Q1	us-gaap	Interest Expense InterestExpense	61416	USD
CY2022Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-162755	USD
CY2021Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-168429	USD
CY2022Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2021Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-51000	USD
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-367131	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-491903	USD
CY2022Q1	bdpt	Weighted Average Number Of Common Shares Outstanding Basic And Diluted WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted	53708187	shares
CY2021Q1	bdpt	Weighted Average Number Of Common Shares Outstanding Basic And Diluted WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted	28148446	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-1093039	USD
CY2022Q1	bdpt	Stock Issued During Period Value Conversion Of Debt StockIssuedDuringPeriodValueConversionOfDebt	52017	USD
CY2022Q1	bdpt	Adjustments To Additional Paid In Capital Other Debts Forgiveness Related Party AdjustmentsToAdditionalPaidInCapitalOtherDebtsForgivenessRelatedParty	10000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-367131	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-1398153	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-1378785	USD
CY2021Q1	bdpt	Stock Issued During Value Settlement For Debt StockIssuedDuringValueSettlementForDebt	75000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	102500	USD
CY2021Q1	bdpt	Stock Issued During Period Value Conversion Of Debt StockIssuedDuringPeriodValueConversionOfDebt	486612	USD
CY2021Q1	bdpt	Common Stock Issued During Period Value Issued For Services CommonStockIssuedDuringPeriodValueIssuedForServices	163900	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-491903	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-1042676	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-491903	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	163900	USD
CY2022Q1	us-gaap	Increase Decrease In Derivative Assets And Liabilities IncreaseDecreaseInDerivativeAssetsAndLiabilities	162755	USD
CY2021Q1	us-gaap	Increase Decrease In Derivative Assets And Liabilities IncreaseDecreaseInDerivativeAssetsAndLiabilities	168429	USD
CY2022Q1	us-gaap	Adjustment For Amortization AdjustmentForAmortization	33167	USD
CY2021Q1	us-gaap	Adjustment For Amortization AdjustmentForAmortization	21875	USD
CY2022Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	17442	USD
CY2021Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	45368	USD
CY2022Q1	bdpt	Gains Losses On Extinguishment Of Debt1 GainsLossesOnExtinguishmentOfDebt1	0	USD
CY2021Q1	bdpt	Gains Losses On Extinguishment Of Debt1 GainsLossesOnExtinguishmentOfDebt1	51000	USD
CY2022Q1	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	21	USD
CY2021Q1	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	-2834	USD
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1178	USD
CY2021Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1526	USD
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	0	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1500	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	89608	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-16222	USD
CY2022Q1	bdpt	Due To Related Party DueToRelatedParty	1803	USD
CY2021Q1	bdpt	Due To Related Party DueToRelatedParty	0	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-61157	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-60361	USD
CY2022Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	1623	USD
CY2021Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	1623	USD
CY2022Q1	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	1623	USD
CY2021Q1	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	1623	USD
CY2022Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	15990	USD
CY2021Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
CY2022Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	50000	USD
CY2021Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	80000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	34010	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	80000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-27147	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	19639	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	82936	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4587	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	55789	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	24226	USD
CY2022Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	USD
CY2021Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	USD
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	4010	USD
CY2021Q1	us-gaap	Interest Paid Net InterestPaidNet	16144	USD
CY2022Q1	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	40000	USD
CY2021Q1	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	40000	USD
CY2022Q1	bdpt	Issuance Of Common Stock For Conversion Of Debt IssuanceOfCommonStockForConversionOfDebt	52017	USD
CY2021Q1	bdpt	Issuance Of Common Stock For Conversion Of Debt IssuanceOfCommonStockForConversionOfDebt	486612	USD
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	0	USD
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	75000	USD
CY2022Q1	us-gaap	Debt Instrument Decrease Forgiveness DebtInstrumentDecreaseForgiveness	10000	USD
CY2021Q1	us-gaap	Debt Instrument Decrease Forgiveness DebtInstrumentDecreaseForgiveness	0	USD
CY2022Q1	us-gaap	Estimate Of Cancellations EstimateOfCancellations	0	USD
CY2021Q1	us-gaap	Estimate Of Cancellations EstimateOfCancellations	35	USD
CY2022Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-size:10pt;font-family:times new roman;margin:0px">The preparation of consolidated financial statements in conformity with US GAAP requires the Company to make estimates and judgments that affect the reported amounts of assets and liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. These estimates and judgments are based on historical information, information that is currently available to the Company, and on various other assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.</p>
CY2022Q1	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	169	USD
CY2022Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	732867	USD
CY2021Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	190	USD
CY2021Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	557042	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-7023240	USD
CY2022Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	169	USD
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	190	USD
CY2022Q1	us-gaap	Revenue Recognition Services Licensing Fees RevenueRecognitionServicesLicensingFees	<p style="font-size:10pt;font-family:times new roman;margin:0px">5. <span style="text-decoration:underline">LICENSE FEE</span></p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px">During the year ended December 31, 2021, the Company entered into three license and royalty agreements for human and animal nutraceutical products, which is currently markets. These agreements are for a period of one year and the Company issued 1,000,000 shares of Series A preferred stock valued at $193,500 in consideration of these licenses. The Company has capitalized the costs associated with licenses.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px">During the three months ended March 31, 2022, and 2021, the Company recognized $33,167 and $21,875 in amortization expenses of license fees, respectively. As of March 31,2022, and December 31,2021, the asset value of the licenses was $26,542 and $59,709, respectively.</p>
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	33167	USD
CY2021Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	21875	USD
CY2022Q1	bdpt	License Cost LicenseCost	26542	USD
CY2021Q1	bdpt	License Cost LicenseCost	59709	USD
CY2022Q1	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	7701	USD
CY2021Q4	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	1750	USD
CY2022Q1	us-gaap	Accrued Salaries Current And Noncurrent AccruedSalariesCurrentAndNoncurrent	241666	USD
CY2021Q4	us-gaap	Accrued Salaries Current And Noncurrent AccruedSalariesCurrentAndNoncurrent	166666	USD
CY2022Q1	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	74551	USD
CY2021Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	68341	USD
CY2022Q1	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	1003	USD
CY2021Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	10993	USD
CY2022Q1	bdpt	Beginning Balance BeginningBalance	557042	USD
CY2022Q1	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	324921	USD
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	247750	USD
CY2022Q1	bdpt	Total Convertible Notes Payable TotalConvertibleNotesPayable	446800	USD
CY2021Q4	bdpt	Total Convertible Notes Payable TotalConvertibleNotesPayable	416450	USD
CY2022Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	38891	USD
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	13333	USD
CY2022Q1	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	407909	USD
CY2021Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	403117	USD
CY2022Q1	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	407909	USD
CY2021Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	403117	USD
CY2022Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	12425	USD
CY2021Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	15516	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	73087	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	63100	USD
CY2022Q1	bdpt	Amortization Of Debt Discount AmortizationOfDebtDiscount	17442	USD
CY2021Q1	bdpt	Amortization Of Debt Discount AmortizationOfDebtDiscount	45368	USD
CY2022Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	22650	USD
CY2022Q1	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	26930	USD
CY2022Q1	bdpt	Debt Discount DebtDiscount	46335	USD
CY2021Q1	bdpt	Debt Discount DebtDiscount	40000	USD
CY2022Q1	us-gaap	Derivative Loss On Derivative DerivativeLossOnDerivative	6335	USD
CY2022Q1	bdpt	Addition Of New Derivatives Recognized As Debt Discounts AdditionOfNewDerivativesRecognizedAsDebtDiscounts	40000	USD
CY2022Q1	bdpt	Addition Of New Derivatives Recognized As Loss On Derivatives AdditionOfNewDerivativesRecognizedAsLossOnDerivatives	6335	USD
CY2022Q1	bdpt	Settled On Issuance Of Common Stock SettledOnIssuanceOfCommonStock	-26930	USD
CY2022Q1	bdpt	Gain Loss On Change In Fair Value Of The Derivative Liabilities GainLossOnChangeInFairValueOfTheDerivativeLiabilities	156420	USD
CY2022Q1	bdpt	Ending Balance EndingBalance	732867	USD
CY2022Q1	bdpt	Loss On Derivative Instruments Related Convertible Notes LossOnDerivativeInstrumentsRelatedConvertibleNotes	6335	USD
CY2021Q1	bdpt	Loss On Derivative Instruments Related Convertible Notes LossOnDerivativeInstrumentsRelatedConvertibleNotes	101805	USD
CY2022Q1	bdpt	Gain Loss On Change In Fair Value Of The Derivative Liabilities GainLossOnChangeInFairValueOfTheDerivativeLiabilities	156420	USD
CY2021Q1	bdpt	Gain Loss On Change In Fair Value Of The Derivative Liabilities GainLossOnChangeInFairValueOfTheDerivativeLiabilities	66624	USD
CY2022Q1	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	162755	USD
CY2021Q1	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	168429	USD
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000	shares
CY2022Q1	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	7540799	shares
CY2022Q1	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	52017	USD
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	58350579	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	50809780	shares
CY2022Q1	bdpt	Common Stock Shares Issuable CommonStockSharesIssuable	10000	shares
CY2022Q1	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	15990	USD
CY2021Q1	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	0	USD
CY2022Q1	us-gaap	Deposit Liabilities Accrued Interest DepositLiabilitiesAccruedInterest	4010	USD
CY2021Q4	us-gaap	Deposit Liabilities Accrued Interest DepositLiabilitiesAccruedInterest	0	USD
CY2022Q1	us-gaap	Interest Paid InterestPaid	232	USD
CY2021Q1	us-gaap	Interest Paid InterestPaid	532	USD
CY2022Q1	bdpt	Notes Payable Related Party NotesPayableRelatedParty	17725	USD
CY2021Q4	bdpt	Notes Payable Related Party NotesPayableRelatedParty	33715	USD
CY2022Q1	bdpt	Notes Payable Accrude Interest NotesPayableAccrudeInterest	1463	USD
CY2021Q4	bdpt	Notes Payable Accrude Interest NotesPayableAccrudeInterest	5241	USD
CY2022Q1	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.04	pure
CY2022Q1	bdpt	Term Of Notes Payable TermOfNotesPayable	P1Y
CY2022Q1	bdpt	Accrued Salary AccruedSalary	75000	USD
CY2022Q1	bdpt	Accrued Salary Payable AccruedSalaryPayable	10000	USD

Files In Submission

Name	View Source	Status
0001640334-22-000978-index-headers.html	Edgar Link	pending
0001640334-22-000978-index.html	Edgar Link	pending
0001640334-22-000978.txt	Edgar Link	pending
0001640334-22-000978-xbrl.zip	Edgar Link	pending
bdpt-20220331.xsd	Edgar Link	pending
bdpt-20220331_cal.xml	Edgar Link	unprocessable
bdpt-20220331_def.xml	Edgar Link	unprocessable
bdpt-20220331_lab.xml	Edgar Link	unprocessable
bdpt-20220331_pre.xml	Edgar Link	unprocessable
bdpt_10q.htm	Edgar Link	pending
bdpt_10qimg1.jpg	Edgar Link	pending
bdpt_10q_htm.xml	Edgar Link	completed
bdpt_ex311.htm	Edgar Link	pending
bdpt_ex312.htm	Edgar Link	pending
bdpt_ex321.htm	Edgar Link	pending
bdpt_ex322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BDPT
BIOADAPTIVES, INC. Stock $bdpt

2022 Q2 Form 10-Q Financial Statement

#000164033422000978 Filed on May 12, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BDPT BIOADAPTIVES, INC. Stock $bdpt

2022 Q2 Form 10-Q Financial Statement

#000164033422000978 Filed on May 12, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BDPT
BIOADAPTIVES, INC. Stock $bdpt